449 related articles for article (PubMed ID: 23114159)
41. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
van Velzen JF; van den Blink D; Bloem AC
Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
[TBL] [Abstract][Full Text] [Related]
42. [Amyloid light chain amyloidosis].
Suzuki K; Shimizu T
Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
[TBL] [Abstract][Full Text] [Related]
43. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
[TBL] [Abstract][Full Text] [Related]
44. Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis.
Chen EC; Rubinstein S; Soto C; Bombardi RG; Day SB; Myers L; Zaytsev A; Majedi M; Cornell RF; Crowe JE
PLoS One; 2020; 15(7):e0235713. PubMed ID: 32634163
[TBL] [Abstract][Full Text] [Related]
45. How we treat systemic light-chain amyloidosis.
Chaulagain CP; Comenzo RL
Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
[TBL] [Abstract][Full Text] [Related]
46. Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis.
Diao X; Li J; Ouyang J; Liu J; Huang B; Chen M; Gu J
Oncol Lett; 2017 Apr; 13(4):2691-2697. PubMed ID: 28454452
[TBL] [Abstract][Full Text] [Related]
47. Light-chain (AL) amyloidosis: diagnosis and treatment.
Sanchorawala V
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1331-41. PubMed ID: 17699366
[TBL] [Abstract][Full Text] [Related]
48. Immunoglobulin light chain amyloidosis.
Merlini G; Comenzo RL; Seldin DC; Wechalekar A; Gertz MA
Expert Rev Hematol; 2014 Feb; 7(1):143-56. PubMed ID: 24350907
[TBL] [Abstract][Full Text] [Related]
49. Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.
Mancio Silva J; Fontes-Carvalho R; Valente D; Almeida C; Cruz AJ; Tente D; Coelho H; Oliveira M; Albuquerque A; Ribeiro VG
Am J Case Rep; 2015 Mar; 16():174-81. PubMed ID: 25803181
[TBL] [Abstract][Full Text] [Related]
50. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
[TBL] [Abstract][Full Text] [Related]
51. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T; D'Souza A; Hari P
F1000Res; 2018; 7():. PubMed ID: 30228867
[TBL] [Abstract][Full Text] [Related]
52. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients.
Perfetti V; Colli Vignarelli M; Anesi E; Garini P; Quaglini S; Ascari E; Merlini G
Haematologica; 1999 Mar; 84(3):218-21. PubMed ID: 10189385
[TBL] [Abstract][Full Text] [Related]
53. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
Puig N; Paiva B; Lasa M; Burgos L; Perez JJ; Merino J; Moreno C; Vidriales MB; Toboso DG; Cedena MT; Ocio EM; Lecumberri R; García de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Pérez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Prosper F; Martinez-Lopez J; Lecrevisse Q; Verde J; Mateos MV; Lahuerta JJ; Orfao A; San Miguel JF
Leukemia; 2019 May; 33(5):1256-1267. PubMed ID: 30542145
[TBL] [Abstract][Full Text] [Related]
54. [AL Amyloidosis].
Ueda M
Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
[TBL] [Abstract][Full Text] [Related]
55. Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis.
Suzuki T; Kusumoto S; Yamashita T; Masuda A; Kinoshita S; Yoshida T; Takami-Mori F; Takino H; Ito A; Ri M; Ishida T; Komatsu H; Ueda M; Ando Y; Inagaki H; Iida S
Ann Hematol; 2016 Jan; 95(2):279-85. PubMed ID: 26555284
[TBL] [Abstract][Full Text] [Related]
56. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
Nasr SH; Said SM; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Dispenzieri A; Buadi FK; Vrana JA; Theis JD; Dogan A; Leung N
Kidney Int; 2013 Mar; 83(3):463-70. PubMed ID: 23302715
[TBL] [Abstract][Full Text] [Related]
57. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
58. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
59. Management of the elderly patient with AL amyloidosis.
Nuvolone M; Milani P; Palladini G; Merlini G
Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
[TBL] [Abstract][Full Text] [Related]
60. Primary (AL) amyloidosis in plasma cell disorders.
Müller AM; Geibel A; Neumann HP; Kühnemund A; Schmitt-Gräff A; Böhm J; Engelhardt M
Oncologist; 2006; 11(7):824-30. PubMed ID: 16880241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
